Labeling is of "infinitely greater regulatory urgency" than the safety criterion in setting regulatory priorities and resource allocation because the vast majority of policy issues involve product claims. GMA does not believe additional labeling regulations are needed. GMA thinks FDA should focus on ensuring that claims on dietary supplements are truthful and not misleading, as well as enforcing the rules against misbranding. GMA also believes FDA should replace its proposed structure/function regulations with a guidance that retains the 1993 definition of disease and excludes indirect implied disease claims from the drug category.
House: Delay OHSA's ergonomics standard Supplement labels
In written testimony to FDA on structure/function claims for dietary supplements, Grocery Manufacturers of America (GMA) says that while consumer safety is obviously FDA's top priority, real risks are few and far between.
Sep 30th, 1999